Login to Your Account



All Eyes on HCV as Pharmasset Ends Clevudine Studies in HBV

By Jennifer Boggs


Tuesday, April 21, 2009
Citing an unfavorable risk-benefit ratio, Pharmasset Inc. said it was dropping late-stage hepatitis B candidate clevudine and refocusing resources to its earlier-stage pipeline aimed at the increasingly crowded hepatitis C virus space. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription